×
About 218 results

ALLMedicine™ Opioid Toxicity Center

Research & Reviews  66 results

Characteristics of fatal 'novel' synthetic opioid toxicity in Australia.
https://doi.org/10.1016/j.drugalcdep.2022.109292
Drug and Alcohol Dependence; Darke S, Peacock A et. al.

Jan 15th, 2022 - Aims: To determine 1. The characteristics of all recorded cases of fatal drug poisoning involving novel synthetic opioids (NSOs) in Australia; 2. The toxicology of cases; and 3. The major autopsy findings. Review of all fatal poisonings related to...

Impact of a Clinical Intervention to Decrease Opioid Prescribing in a Postcesarean Deli...
https://doi.org/10.1016/j.jogc.2021.11.009
Journal of Obstetrics and Gynaecology Canada : JOGC = Jou... Brar S, Aujla S et. al.

Dec 2nd, 2021 - A quality assurance study was completed following the implementation of a standardized opioid prescribing and education protocol post cesarean delivery. The primary goal was to determine the need for a policy on postpartum opioid prescribing pract...

Opioid Toxicity Treatment & Management
https://emedicine.medscape.com/article/815784-treatment

Oct 21st, 2021 - Prehospital Care Adequate prehospital care hinges on aggressive airway control. Expedient endotracheal intubation is indicated for patients who are unable to protect their airway. In patients lacking spontaneous respirations, orotracheal intubatio...

Opioid Toxicity Medication
https://emedicine.medscape.com/article/815784-medication

Oct 21st, 2021 - Medication Summary Naloxone is a pure competitive antagonist of opioid receptors and lacks any agonist activity. Adverse effects are rare at therapeutic doses. Effects of withrawal may follow administration, and may be confused as adverse effects ...

Opioid Toxicity
http://emedicine.medscape.com/article/815784-overview

Oct 21st, 2021 - Practice Essentials Opioids are prescribed widely, often in concert with other analgesics, and this legitimate use, along with diversion of pharmaceutical opioids and abuse of illicit opioids, results in large numbers of overdoses. In 2019, opioid...

see more →

Drugs  7 results see all →

Clinicaltrials.gov  4 results

Safety, Tolerability and Pharmacokinetics of Single Ascending Doses of REL-1017 (d-Methadone)
https://clinicaltrials.gov/ct2/show/NCT03637361

Aug 1st, 2019 - This was a phase 1, single-center study carried out in healthy male and female subjects to investigate the safety, tolerability, and PK of d-methadone. This was a double-blind, randomized, placebo-controlled study in 6 sequential cohorts of health...

Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of REL-1017 (d-Methadone)
https://clinicaltrials.gov/ct2/show/NCT03638869

Aug 20th, 2018 - This was a phase 1, single-center study carried out in healthy male and female subjects to investigate the safety, tolerability, and PK of multiple doses (25mg, 50mg, and 75mg once daily) of d-methadone for 10 days. It was a double-blind, randomiz...

Naloxone Auto-injector as a Universal Precaution for Patients With Opioid Substance Use Disorder
https://clinicaltrials.gov/ct2/show/NCT02669901

Oct 26th, 2016 - The purpose of this pilot-study is to to distribute naloxone auto-injector in a "Universal Precaution" manner to patients with opioid substance use disorder. The objectives are to decrease the number of fatal and nonfatal overdose deaths, to exami...

A Study of ULTRAM ER at Two Dose Levels in Adolescents With Pain
https://clinicaltrials.gov/ct2/show/NCT01586507

Aug 29th, 2012 - This is a multicenter, open-label (all people know the identity of the intervention), 2-group, single dose study. Within each group of participants for Parts 1 and 2, at least 1/3 of the participants will be female, at least 1/3 of the participant...

see more →

News  10 results

Management of Acute Opioid Toxicity in the Outpatient Setting
https://www.mdedge.com/dermatology/article/226936/mixed-topics/management-acute-opioid-toxicity-outpatient-setting
H. Harris Reynolds, MD, Timothy J. Orlowski, MD et. al.

Aug 13th, 2020 - Dermatologists’ offices are not immune from potentially fatal medical events. As a result, it is imperative that dermatologists are well versed in how to manage emergency situations in an outpatient setting.

FDA Warns Sellers of Illegal Tianeptine Supplements
https://www.medscape.com/viewarticle/905431

Nov 21st, 2018 - The US Food and Drug Administration (FDA) has sent warning letters to two companies illegally marketing dietary supplements containing the unapproved antidepressant tianeptine (Stablon, Serdia Pharmaceuticals), which the companies claim can reliev...

Assessing adverse events tied to outpatient opioid use in children
https://www.mdedge.com/neurology/article/170349/pain/assessing-adverse-events-tied-outpatient-opioid-use-children
Heidi Splete

Jul 16th, 2018 - Nearly three-quarters of opioid-related adverse events seen in children were related to therapeutic opioid use, based on data from more than a million prescriptions. BackyardProduction/Thinkstock Prescription of opioids to children for outpatient.

Reports of Incidental Fentanyl Exposure Exaggerate Danger (STAT)
https://www.medpagetoday.com/emergencymedicine/emergencymedicine/67203

Aug 10th, 2017 - Media reports linking brief, incidental fentanyl exposure to opioid toxicity may exaggerate the dangers to first responders and others, according to STAT News. Although the synthetic opioid is 50 to 100 times more potent than morphine, experts tol...

Fast Five Quiz: Do You Know About Newer Drugs of Abuse?
https://reference.medscape.com/viewarticle/867291_5

Aug 11th, 2016 - Fentanyl is significantly more potent than morphine and heroin, such that even low doses may be fatal. From 2004 to 2011, increases in abuse of opioids were as follows: Hydromorphone: 438% Oxycodone: 263% Morphine: 146% Hydrocodone: 107% Fentanyl:...

see more →